Novo Nordisk says oral version of Wegovy also works at reducing weight in a PhIII study
An oral version of Novo Nordisk’s obesity medication helped adults in a Phase III clinical trial lose up to 15% of their body weight, setting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
